CoChat
Sign Up
Cited by 142Prostate Cancer Treatment and ResearchBone health and treatmentsManagement of metastatic bone disease

Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer

Fizazi, Karim, Massard, Christophe, Smith, Matthew, Rader, Michael, Brown, Janet, Milecki, Piotr, Shore, Neal, Oudard, Stephane +6 more·2015·European Urology
DOI 10.1016/j.eururo.2014.10.001
Open this paper in CoChat — free account

Abstract

Background Previous studies have reported on prognostic factors for castration-resistant prostate cancer (CRPC); however, most of these studies were conducted before docetaxel chemotherapy was approved for CRPC. Objective To evaluate the prognostic value of multiple parameters in men with bone metastases due to CRPC using a contemporary dataset. Design, setting, and participants The analysis included 1901 patients with metastatic CRPC enrolled in an international, multicenter, randomized, double-blind phase 3 trial conducted between May 2006 and October 2009. Outcome measures and statistical analysis We developed multivariate validated Cox proportional hazards models and nomograms to estimate 12-mo and 24-mo survival probabilities and median survival time. Results and limitations The median (95% confidence interval) overall survival was 20 (18, 21) mo. The final model included 12 of the 15 potential prognostic variables evaluated (concordance index 0.72). Seven bone-related variables were associated with longer survival in the final model: alkaline phosphatase ≤143 U/l (p 128g/l (p Conclusions Bone-related parameters are strong prognostic variables for overall survival in patients with bone metastases from CRPC. Patient summary Survival time is variable in patients with bone metastases from prostate cancer. We found that factors related to bone help to predict how long a patient will live.

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2014.10.001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Fizazi, K., Massard, C., Smith, M., Rader, M., Brown, J., Milecki, P., Shore, N., Oudard, S., Karsh, L., Carducci, M., Damião, R., Wang, H., Ying, W., & Goessl, C.
Affiliations
  • Université Paris-Sud (FR)
  • Massachusetts General Hospital (US)
  • Nyack Hospital (US)
  • Cancer Research UK (GB)
  • Poznan University of Medical Sciences (PL)
  • Carolina Urologic Research Center (US)
  • The Urology Center of Colorado (US)
  • Johns Hopkins University (US)
  • Hospital Universitário Pedro Ernesto (BR)
  • Amgen (United States) (US)
Corresponding author
Fizazi, Karim
ORCID
Venue
European Urology
Publisher
Elsevier BV
Published
2015-07
Volume
68
Issue
1
Pages
42-50
ISSN
0302-2838 (ISSN-L)
DOI
10.1016/j.eururo.2014.10.001
OpenAlex
W2065574422
Cited by
142
References
26
Citations by year
2026: 6 · 2025: 12 · 2024: 6 · 2023: 8 · 2022: 15 · 2021: 7 · 2020: 11 · 2019: 15 · 2018: 16 · 2017: 16 · 2016: 17 · 2015: 12 · 2014: 1
FWCI
12.30
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Urology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Francis Crick Institute (10048)
  • Cancer Research UK (20925, 10048)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords
castration-resistant prostate cancer, bone metastasis, overall survival, prognostic factors, bone-specific alkaline phosphatase, urinary N-telopeptide, alkaline phosphatase, pain, skeletal-related events, nomogram, docetaxel, visceral metastases, hemoglobin, prostate-specific antigen, ECOG performance status, age, metastatic castration-resistant prostate cancer
MeSH terms
Denosumab, Zoledronic Acid, Adult, Age Factors, Aged, Aged, 80 and over, Alkaline Phosphatase, Bone Neoplasms, Diphosphonates, Double-Blind Method, Hemoglobins, Humans, Imidazoles, Kallikreins, Male, Middle Aged, Peptides, Prognosis, Multivariate Analysis, Proportional Hazards Models, Prostate-Specific Antigen, Collagen Type I, Bone Density Conservation Agents, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review